FreshPatents.com Logo


new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)


Similar
Filing Names

Merck Sharp x26 Dohme Corp
Merck Sharp x26 Dohme Corporation
Merck Sharp x26 Dohme Corp And Northwestern University
Merck Sharp x26 Dohme Corp_20131212

Popular
Companies


Web
Adobe patents
Amazon patents
Apple patents
Ebay patents
Facebook patents
Google patents
IBM patents
Linkedin patents
Microsoft patents
Oracle patents
Red Hat patents
Yahoo patents

Food/Health
Adidas
Nike patents
Pfizer patents
Monsanto patents
Medtronic patents
Kraft patents

Transportation
Boeing patents
Tesla Motors patents

Telecom
Qualcomm patents
Motorola patents
Nokia patents
RIMM patents

Industrial/Electronics
AMD
Applied Materials
Seagate patents
General Electric
Caterpillar patents
Samsung
Wal-mart patents

Ticker Symbols

Merck Sharp & Dohme Corp patents


      
Recent patent applications related to Merck Sharp & Dohme Corp. Merck Sharp & Dohme Corp is listed as an Agent/Assignee. Note: Merck Sharp & Dohme Corp may have other listings under different names/spellings. We're not affiliated with Merck Sharp & Dohme Corp, we're just tracking patents.

ARCHIVE: New 2015 2014 2013 2012 2011 2010 2009 | Company Directory "M" | Merck Sharp & Dohme Corp-related inventors



Search recent Press Releases: Merck Sharp & Dohme Corp-related press releases
Count Application # Date Merck Sharp & Dohme Corp patents (updated weekly) - BOOKMARK this page
12015001159001/08/15Dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
22012025303210/04/12Novel cationic lipids with short lipid chains for oligonucleotide delivery
32012020281908/09/12Combination therapy using a beta 3 adrenergic receptor agonists and an antimuscarinic agent
42015002080601/22/15 new patent  Dry powder inhaler for delivering multipe agglomerate formulations
52015002395201/22/15 new patent  Anti-addl monoclonal antibody and uses thereof
62015002407101/22/15 new patent  Inhibitors of catechol o-methyl transferase and their use in the treatment of psychotic disorders
72015002504601/22/15 new patent  Preparation and use of bicyclic himbacine derivatives as par-1 receptor antagonists
82015001768601/15/15Methods for reducing mannosyltransferase activity in lower eukaryotes
92015001839901/15/15Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
102015001056401/08/15Immunoregulation by anti-ilt5 antibodies and ilt5-binding antibody fragments
112015000460801/01/15Monocyte-derived nucleic acids and related compositions and methods
122015000533001/01/15Piperidinone carboxamide azaindane cgrp receptor antagonists
132014037726012/25/14Protective vaccine based on staphylococcus aureus sa2074 protein
142014037849312/25/14Fused bicyclic oxazolidinone cetp inhibitor
152014037002512/18/14Uses of mammalian cytokines and agonists; related reagents
162014037113812/18/14Inhibitors of hepatitis c virus replication
172014034997211/27/14Substituted pyrimidines
182014034884111/27/14Anti-gitr antibodies
192014034999811/27/14Pyrrolopyrimidines as janus kinase inhiitors
202014035000211/27/14Imidazopyridin-2-one derivatives
212014034307111/20/14Compositions and methods for treating cancer
222014033619611/13/14Phosphoric acid salts of sitagliptin
232014032927611/06/14Methods for increasing n-glycan occupancy and reducing production of hybrid n-glycans in pichia pastoris strains lacking alg3 expression
242014032351910/30/14Heterocyclic compounds as b-raf inhibitors for treatment of cancer
252014029620210/02/14Substituted piperidinyl compounds useful as gpr119 agonists
262014029622110/02/14Iminothiadiazine dioxide compounds as bace inhibitors, compositions, and their use
272014029622210/02/14Iminothiadiazine dioxide compounds as bace inhibitors, compositions, and their use
282014027501709/18/14Cgrp receptor antagonists
292014025681809/11/14Nano-suspension process
302014024428908/28/14Cold storage system for storing pharmaceutical product containers
312014023429608/21/14Stable formulations of antibodies to human programmed death receptor pd-1 and related treatments
322014023430108/21/14Modulation of pilr to treat immune disorders
332014023553708/21/14N-glycosylated insulin analogues
342014022562708/14/14Device for calibrating and verifying the integrity of resistivity-based sensing probes
352014022722308/14/14Pegylated interleukin-10
362014022725008/14/14Stable formulations of antibodies to tslp
372014022729008/14/14Method for increasing n-glycosylation site occupancy on therapeutic glycoproteins produced in pichia pastoris
382014022729208/14/14Anti-mcam antibodies and associated methods of use
392014022002708/07/141d05 pcsk9 antagonists
402014022138308/07/14Cetp inhibitors
412014021241207/31/14Use of il-33 antagonists to treat fibrotic disease
422014020656307/24/14Biomarkers for psoriasis
432014020664007/24/142'-azido substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
442014020664107/24/14Remedy
452014020666507/24/14Selective glycosidase inhibitors and uses thereof
462014020667507/24/14Iminothiadiazine dioxide compounds as bace inhibitors, compositions, and their use
472014020671507/24/14Preparation and use of compounds as protease inhibitors
482014020018007/17/14Method for producing proteins in pichia pastoris that lack detectable cross binding activity to antibodies against host cell antigens
492014020021307/17/142-spiro-substituted iminothiazines and their mono-and dioxides as bace inhibitors, compositions and their use
502014017015406/19/14Engineered anti-il-23r antibodies
512014017065806/19/14Mammalian cytokines; related reagents
522014017143706/19/14Oxazole derivatives useful as inhibitors of faah
532014017145606/19/14Fused tricyclic compounds as mtor inhibitors
542014017148006/19/14Crystalline polymorphic forms of an antidiabetic compound
552014016177006/12/142'-cyano substituted nucleoside derivatives and methods of use thereof useful for the treatment of viral diseases
562014016179806/12/14Anti-pcsk9 and methods for treating lipid and cholesterol disorders
572014014744205/29/14Use of il-23 antagonists for treatment of infection
582014014746105/29/14Polypeptides for inducing a protective immune response against staphylococcus aureus
592014014095405/22/14Methods of modulating cytokine activity; related reagents
602014014101205/22/14Engineered anti-tslp antibody
612014014144405/22/14Isolated mammalian monocyte cell genes; related reagents
622014014144505/22/14Isolated mammalian monocyte cell genes; related reagents
632014014211505/22/14Inhibitors of the renal outer medullary potassium channel
642014012836105/08/14Cyclic amide bace-1 inhibitors having a benzamide substituent
652014012836705/08/14Cycloalkyl-fused tetrahydroquinolines as crth2 receptor modulators
662014012836805/08/14Substituted cyclopropyl compounds, compositions containing such compounds, and methods of treatment
672014012003705/01/14Method for detection of amyloids beta oligomers in a fluid sample and uses thereof
682014011291904/24/14Interleukin-10 antibodies
692014011392004/24/14Tricyclic heterocycles useful as dipeptidyl peptidase-iv inhibitors
702014010588704/17/14Methods for modulating il-33 activity
712014010641304/17/14Immobilized transaminases and process for making and using immobilized transaminase
722014010734604/17/14Process for preparing chiral dipeptidyl peptidase-iv inhibitors
732014009356404/03/14Pharmaceutical compositions of combinations of dipeptidyl peptidase-4 inhibitors with simvastatin
742014009387504/03/14Mammalian cytokines; receptors; related reagents and methods
752014008804803/27/14Diazeniumdiolate cyclohexyl derivatives
762014008088403/20/14Novel crystalline forms of a dipeptidyl peptidase-iv inhibitor
772014005789302/27/14Substituted cycloproply compounds, compositions containing such compounds and methods of treatment
782014005174002/20/14Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
792014004574602/13/14Antidiabetic tricyclic compounds
802014004582902/13/14Substituted 1,3-benzothiazol-2(3h)-ones and [1,3]thiazolo[5,4-b]pyridin-2(1h)-ones as positive allosteric modulators of mglur2
812014004583202/13/14Insulin-like growth factor-1 receptor inhibitors
822014003762702/06/14Modulation of pilr receptors to treat microbial infections
832014003894202/06/14Rorgammat inhibitors
842014003897002/06/14Bridged and fused antidiabetic compounds
852014003025501/30/14Methods of predicting cancer cell response to therapeutic agents
862014003076001/30/14Pavec
872014003125101/30/14Methods of classifying human subjects with regard to cancer prognosis
882014003134901/30/14Inhibitors of the renal outer medullary potassium channel
892014002366701/23/14Pyrrolidine-fused thiadiazine dioxide compounds as bace inhibitors, compositions, and their use
902014000518201/02/14Aryl methyl benzoquinazolinone m1 receptor positive allosteric modulators
912013034451212/26/13Cd16a reporter assay for evaluation of adcc potential of biologics
922013033137212/12/13Cyclic amine substituted oxazolidinone cetp inhibitor
932013032323912/05/13Modulation of pilr receptors to treat sepsis
942013032324612/05/13Use of mdl-1 antagonists to treat spondylarthropathy
952013032325112/05/13Use of il-23 and il-17 antagonists to treat autoimmune ocular inflammatory disease
962013032448312/05/13Mammalian cell surface antigens; related reagents
972013032461012/05/13Cathepsin cysteine protease inhibitors
982013032472812/05/13Process for the preparation of an orexin receptor antagonist
992013031635411/28/13Mammalian cytokine; related reagents
1002013029627811/07/13Diazeniumdiolate derivatives
1012013028776310/31/13Combination therapy for treating cancer comprising an igf-1r inhibitor and an akt inhibitor
1022013028021410/24/13Polycyclic heterocycle derivatives and methods of use thereof for the treatment of viral diseases
1032013028147410/24/13Fused tricyclic inhibitors of mammalian target of rapamycin
1042013026114010/03/13Tricyclic heterocycles useful as dipeptidyl peptidase-iv inhibitors
1052013025167709/26/13Genetic markers associated with interferon-alpha response
1062013024369209/19/13Fdg-pet evaluation of ewing's sarcoma sensitivity
1072013023751809/12/13Novel compounds that are erk inhibitors
1082013023085509/05/13Monocyte-derived nucleic acids and related compositions and methods
1092013022558208/29/13Biaryl-spiroaminooxzaoline analogues as alpha 2c adrenergic receptor modulators
1102013022583608/29/13Novel low molecular weight cyclic amine containing cationic lipids for oligonucleotide delivery
1112013021657508/22/13Recombinant subunit dengue virus vaccine
1122013021769508/22/13Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
1132013021775608/22/13Rna interference mediated inhibition of gene expression using short interfering nucleic acids (sina)
1142013021776608/22/13Formulations for cathepsin k inhibitors
1152013020306008/08/13Mammalian genes; related reagents
1162013018927807/25/13Antagonists of pcsk9
1172013015794006/20/13Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
1182013015672906/20/13Mammalian receptor proteins; related reagents and methods
1192013015677106/20/13Fdf03 antibodies and uses thereof
1202013015036206/13/13Novel pyrazolo[1,5-a]pyrimidine derivatives as mtor inhibitors
1212013014385906/06/13Novel prolylcarboxypeptidase inhibitors
1222013013104105/23/13Spirocyclic compounds
1232013013104205/23/13Spiroxazolidinone compounds
1242013012200905/16/13Engineered anti-il-23p19 antibodies
1252013012320005/16/13Mammalian cell surface antigens; related reagents
1262013012323705/16/13Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
1272013011522305/09/13Antagonists of pcsk9
1282013011623105/09/13Tyrosine kinase inhibitors
1292013010973905/02/13Compositions and methods for short interfering nucleic acid inhibition of nav1.8
1302013009605304/18/13Posaconazole intravenous solution formulations stabilized by substituted beta-cyclodextrin
1312013007139003/21/13Method for preparing antibodies having improved properties
1322013006481703/14/13Engineered anti-il-23r antibodies
1332013005985003/07/13Aza-indole derivatives useful as modulators of faah
1342013005335202/28/13Diazeniumdiolate cyclopentyl derivatives
1352013004591402/21/13Biaryl spiroaminooxazoline analogues as alpha2c adrenergic receptor modulators
1362013004092902/14/13Novel prolylcarboxypeptidase inhibitors
1372013004093202/14/13Substituted aryl sulfone derivatives as calcium channel blockers
1382013003456102/07/13Isolated mammalian monocyte cell genes; related reagents
1392013003531202/07/13Cathepsin cysteine protease inhibiors
1402013002351501/24/13Novel spiropiperidine prolylcarboxypeptidase inhibitors
1412013001804801/17/13Oxazole derivatives useful as modulators of faah
1422013001252601/10/13Oxazole derivatives useful as modulators of faah
1432013000579701/03/13Endosomolytic poly(amidoamine) disulfide polymers for the delivery of oligonucleotides
1442013000451801/03/13Cyclic amine bace-1 inhibitors having a benzamide substituent
1452012032967912/27/12Eukaryotic cell display systems
1462012031532112/13/12Immunological methods and compositions for the treatment of alzheimer's disease
1472012031620012/13/12Pyridone derivatives
1482012027724011/01/12Substituted aminotetrahydrothiopyrans and derivatives thereof as dipeptidyl peptidase-iv inhibitors for the treatment of diabetes
1492012026477710/18/12Oxadiazole beta carboline derivatives as antidiabetic compounds
1502012023200709/13/12Method for producing proteins in pichia pastoris that lack detectable cross binding activity to antibodies against host cell antigens
1512012023208609/13/12Fused tricyclic compounds with adenosine a2a receptor antagonist activity
1522012022588609/06/12Novel pyrrolidine derived beta 3 adrenergic receptor agonists
1532012021484608/23/12Hexahydrocyclopentyl[f]indazole pyridyl ethanols and derivatives thereof as selective glucocorticoid receptor modulators
1542012021484708/23/122-[1-phenyl-5-hydroxy-4a-substituted-hexahydrocyclopenta[f]indazol-5-yl]ethyl phenyl derivatives as glucocorticoid receptor ligands
1552012020188508/09/12Pharmaceutical compositions of combinations of dipeptidyl peptidase-4 inhibitors with pioglitazone
1562012019690108/02/12Tertiary amide orexin receptor antagonists
1572012019070107/26/12Renin inhibitors
1582012017868107/12/12Bipiperidinyl compounds, compositions, containing such compounds and methods of treatment
1592012017875007/12/12Niacin receptor agonists, compositions containing such compounds and methods of treatment
1602012017239707/05/12Hexahydrocyclopenta[f]indazole 5-yl ethanols and derivatives thereof as selective glucocorticoid receptor modulators
1612012016415806/28/12Anti-addl monoclonal antibody and use thereof
1622012015743806/21/12Pyranyl aryl methyl benzoquinazolinone m1 receptor positive allosteric modulators
1632012015743206/21/12Novel pyrrolidine derived beta 3 adrenergic receptor agonists
1642012014277006/07/12Pharmaceutical compositions of hdac inhibitors and chelatable metal compounds, and metal-hdac inhibitor chelate complexes
1652012014269406/07/12Substituted 4-hydroxypyrimidine-5-carboxamides
1662012014275206/07/12Hiv protease inhibitors
1672012013601205/31/12Amino tetrahydro-pyridopyrimidine pde10 inhibitors
1682012012162405/17/12Hepatitis c virus ns3 protease inhibitors
1692012011913005/17/12Diaphragm valve with improved sealing performance and leak detection
1702012012150805/17/12Radiolabeled cgrp antagonists
1712012012158005/17/12Methods for producing high concentration lyophilized pharmaceutical formulations
1722012012289905/17/12Piperidinone carboxamide azaindane cgrp receptor antagonists
1732012012290005/17/12Piperidinone carboxamide azaindane cgrp receptor antagonists
1742012012291105/17/12Piperidinone carboxamide azaindane cgrp receptor antagonists
1752012011589405/10/12Imidazole derivatives useful as modulators of faah and as faah imaging agents
1762012011592105/10/12Fluoro substituted cycloalkanoindoles, compositions containing such compounds and methods of treatment
1772012010860005/03/12Substituted 4-hydroxypyrimidine-5-carboxamides
1782012009500104/19/12Substituted-1,3,8-triazaspiro[4.5]decane-2,4-diones
1792012009505504/19/12Hexahydrocyclopentyl[f]indazole 5-hydroxymethyl ethanols and derivatives thereof as selective glucocorticoid receptor modulators
1802012008348304/05/12Inhibitors of hepatitis c virus replication
1812012008267904/05/12Antagonists of pcsk9
1822012008268004/05/12Antagonists of pcsk9
1832012007679903/29/12Antagonists of pcsk9
1842012007796403/29/12Antagonists of pcsk9
1852012005318103/01/12Pyrrolidine-derived beta 3 adrenergic receptor agonists
1862012004097802/16/12Heterocyclic fused cinnoline m1 receptor positive allosteric modulators
1872012003460802/09/12Microrna as a biomarker of pancreatic islet beta-cell engagement
1882012003521402/09/12Renin inhibitors
1892012003524702/09/12Rna interference mediated inhibition of signal transducer and activator of transcription 6 (stat6) gene expression using short interfering nucleic acid (sina)
1902012002894002/02/12Functionally selective azanitrile alpha-2c adrenoreceptor agonists
1912012002905402/02/12Rna interference mediated inhibition of gata binding protein 3 (gata3) gene expression using short intefering nucleic acid (sina)
1922012002214301/26/12Rna interference mediated inhibition of the thymic stromal lymphopoietin (tslp) gene expression using short interfering nucliec acid (sina)
1932012002107401/26/12P2x3, receptor antagonists for treatment of pain
1942012002194801/26/12Surface display of whole antibodies in eukaryotes
1952012002214201/26/12Rna interference mediated inhibition of signal transducer and activator of transcription 1 (stat1) gene expression using short interfering nucleic acid (sina)
1962012001601001/19/12Rna interference mediated inhibition of btb and cnc homology 1, basic leucine zipper transcription factor 1 (bach1) gene expression using short interfering nucleic acid (sina)
1972012001601101/19/12Rna interference mediated inhibition of connective tissue growth factor (ctgf) gene expression using short interfering nucleic acid (sina)
1982012000958001/12/12Methods for quantitating small rna molecules
1992012001019301/12/12Cgrp receptor antagonists
2002012001027201/12/12Rna interference mediated inhibition of apoptosis signal-regulating kinase 1 (ask1) gene expression using short interfering nucleic acid (sina)
2012012000428101/05/12Rna interference mediated inhibition of the nerve growth factor beta chain (ngfb) gene expression using short interfering nucleic acid (sina)
2022012000428201/05/12Rna interference mediated inhibition of the intercellular adhesion molecule 1 (icam-1) gene expression using short interfering nucleic acid (sina)
2032012000428001/05/12Rna interference mediated inhibition of the high affinity 1 ge receptor alpha chain (fc epsilon r1 alpha) gene expression using short interfering nucleic acid (sina)
2042011031291112/22/11Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
2052011030107912/08/11Neuromedin u receptor agonists and uses thereof
2062011029469612/01/11Methods for characterizing agonists and partial agonists of target molecules
2072011029473512/01/11Mechanism of neuromedin u action and uses thereof
2082011029477712/01/11Beta-lactamase inhibitors
2092011026353310/27/11Novel cyclic benzimidazole derivatives useful as anti-diabetic agents
2102011025059110/13/11Method of designing sirnas for gene silencing
2112011025120710/13/11Biaryl-spiroaminooxazoline analogues as alpha 2c adrenergic receptor modulators
2122011024051110/06/11Packaging for oxygen-sensitive pharmaceutical products
2132011023763409/29/11Novel crystalline forms of an inhibitor of 11-beta-hydroxysteroid dehydrogenase type 1
2142011022950809/22/11Polypeptides for inducing a protective immune response against staphylococcus aureus
2152011023049809/22/11Biaryl carboxamides
2162011023052609/22/11Thiazolyl mglur5 antagonists and methods for their use
2172011022419309/15/11Inhibitors of diacylglycerol acyltransferase
2182011022413409/15/11Macrocyclic quinoxaline compounds as hcv ns3 protease inhibitors
2192011022419509/15/11Heterocyclic compounds as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
2202011021817409/08/11Novel cyclic benzimidazole derivatives useful as anti-diabetic agents
2212011021820209/08/11Soluble guanylate cyclase activators
2222011020773708/25/11Substituted bicyclic amines for the treatment of diabetes
2232011020794208/25/11Intermediate compounds for the preparation of trans-5-chloro-2-methyl-2,3,3a,12b-tetrahydro-1h-dibenz[2,3:6,7]-oxepino[4,5-c]pyrrole
2242011020162108/18/11Angiotensin ii receptor antagonists
2252011019595708/11/11Substituted diazepan orexin receptor antagonists
2262011019030808/04/11Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
2272011019034608/04/11Diphenyl substituted alkanes as flap inhibitors
2282011017805907/21/111,3-oxazolidin -2-one derivatives useful as cetp inhibitors
2292011017811707/21/11Oxazolobenzimidazole derivatives
2302011017881907/21/11Devices and methods for determining a patient's propensity to adhere to a medication prescription
2312011017220507/14/11Monocyclic amide cgrp receptor antagonists
2322011015230406/23/11Spiroazaindoles
2332011013676906/09/11Method of treating men with testosterone supplement and 5alpha-reductase inhibitor
2342011012466105/26/11Oxazolobenzimidazole derivatives
2352011011833705/19/11Method of using compositions comprising mir-192 and/or mir-215 for the treatment of cancer
2362011011197605/12/11Microrna biomarkers of tissue injury
2372011011206405/12/11Pyridyl amide t-type calcium channel antagonists
2382011011207705/12/11Quinolizidinone m1 receptor positive allosteric modulators
2392011007672103/31/11Efficient production of heterologous proteins using mannosyl transferase inhibitors
2402011006566903/17/11Oxazolobenzimidazole derivatives
2412011006577803/17/11Rna interference mediated inhibition of muscarinic colinergic receptor gene expression using short interfering nucleic acid (sina)
2422011005392703/03/11Nanoparticle formation via rapid precipitation
2432011004614502/24/11Quinolizidinone m1 receptor positive allosteric modulators
2442011002151601/27/11Monocyclic cgrp receptor antagonists
2452011001586901/20/11Methods and gene expression signature for assessing growth factor signaling pathway regulation status
2462010033017712/30/10Pharmaceutical compositions of a combination of metformin and a dipeptidyl peptidase-iv inhibitor
2472010032402312/23/10Imidazobenzazepine cgrp receptor antagonists
2482010032402412/23/10Quinolizidinone m1 receptor positive allosteric modulators
2492010032408812/23/10Fused pyridone m1 receptor positive allosteric modulators


ARCHIVE: New 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Merck Sharp & Dohme Corp in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Merck Sharp & Dohme Corp with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###

     SHARE